News and Announcements
Collaborate (ASX:CL8) Raises $3.5m, Receives $1m Investment from RACV & Reports Record Cash Receipts
- Published August 10, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Collaborate Corporation Limited (ASX:CL8) has recently announced the consolidated quarterly cash flow report and business updated for the quarter ended 30 June 2017.
KEY TAKEAWAYS:
- Exercise of 100% of CL80 listed options raising a total of $3,500,295
- Strategic investment of $1 million received from RACV at an issue price of $0.03 per share, a 20% premium to the last closing price prior to issue.
- Collaborate and RACV are working to jointly realise peer-to-peer rental opportunities in the sharing economy in Victoria (for RACV’s 2.1 million members and the wider Victorian market.
- $3.6 million cash held at the end of June 2017, an increase of $3.4 million versus March 2017 Quarter.
- 56% increase in receipts, the June Quarter produced the highest ever cash receipts achieved by the company from its peer-to-peer operations.
- Significant progress with development and launch planning for the Mobilise business.
- Significant progress in incubating a new peer-to-peer business.
Company Updates
The Biofilm Breakthrough: How An Australian BioTech Firm Is Tapping Indonesia’s $45,000-a-Kitchen Bottleneck
Australian sustainability and deep-tech firm Altair International Pty Ltd is commercialising plant-based clinical hygiene technology, targeting a prime operational bottleneck in Indonesia’s massive national free meals program. Every few years, an Australian deep-tech company emerges combining proprietary science with a transformational anchor contract, the kind of business that quietly creates an entirely new market category […]
THE TAX CHANGED. NOW THE PRODUCT IS CHANGING TO MATCH.
Changes to the 50% capital gains tax discount are shifting Australian private capital away from growth and into high-yielding wrappers. Fund managers are actively redesigning products across private credit and property to capture the incoming capital rotation
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Backed By Leading Investment Groups and Family Offices
